Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.

FEBS letters - 3 Sept 2009

Healy Eamonn F, Johnson Skylar, Hauser Charles R, King Peter J

Abstract excerpt

The conformational flexibility exhibited by protein kinases poses an enormous challenge to the design of cancer therapeutics. Additionally the high degree of structural conservation within the kinase superfamily often leads to inhibitors that exhibit little selectivity and substantial cross react...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Hydrogen Bonding
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Proto-Oncogene Proteins c-abl

Share to Proto-Oncogene Proteins c-kit

Share to Receptor, Fibroblast Growth Factor, Type 2

Source

Identifiers

PMID: 19660459
DOI: 10.1016/j.febslet.2009.07.051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19660459-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.PMID 19660459Read ↗

Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.Semantic proximity Read ↗

c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic PenaltySemantic proximity Read ↗

Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases.Semantic proximity Read ↗

Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.Semantic proximity Read ↗

Revealing imatinib-kinase specificity via analyzing changes in protein dynamics and computing molecular binding affinitySemantic proximity Read ↗

Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational DynamicsSemantic proximity Read ↗

Induced disorder in protein-ligand complexes as a drug-design strategy.Semantic proximity Read ↗

Activation of tyrosine kinases by mutation of the gatekeeper threonine.Semantic proximity Read ↗

Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.Semantic proximity Read ↗

Conformational disturbance in Abl kinase upon mutation and deregulation.Semantic proximity Read ↗

Kinase dynamics. Using ancient protein kinases to unravel a modern cancer drug's mechanism.Semantic proximity Read ↗

A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.